Year: 2024
Type: article
Abstract: Glioblastoma multiforme (GBM) is the most lethal and common primary malignant brain tumour. It has a 100% mortality rate and poor prognosis, and is currently incurable. Conventional treatments, such as surgery, can only extend patients’ survival to a very limited extent and are often accompanied by severe side effects. In recent decades, chimeric antigen receptor (CAR) T-cells therapy has emerged as a novel immunotherapy with great potential in treating various tumours, raising high expectations for its application in GBM. This paper reviews the structure and function of CAR design and discusses three antigens on GBM that have completed clinical trials: EGFRvIII, HER2 and IL-13Ra2. Although each antigen-specific CAR T-cell therapy face its own challenges, the results from clinical trials have been overall inspiring. However, CAR T-cell therapy for GBM is still in very early stages and requires further research and exploration.
Source: Theoretical and Natural Science
Author: Zilong Pang
Language: English
Topic: CAR-T cell therapy research
Subfield: Oncology
Field: Medicine
Domain: Health Sciences
Open Access status: hybrid
OpenAlex ID: W4405820703